Patents by Inventor Donald G. Musson
Donald G. Musson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873525Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: May 23, 2023Date of Patent: January 16, 2024Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11845977Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: May 23, 2023Date of Patent: December 19, 2023Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20230313265Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: May 23, 2023Publication date: October 5, 2023Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20230295685Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: May 23, 2023Publication date: September 21, 2023Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20230034700Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceuticaliy acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: March 4, 2022Publication date: February 2, 2023Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 11274332Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 15, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11274331Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 15, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11268128Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 8, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20220042068Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: October 15, 2021Publication date: February 10, 2022Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20220033877Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20220033876Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 11060128Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: September 1, 2020Date of Patent: July 13, 2021Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20210002693Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20210002694Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20200407772Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 1, 2020Publication date: December 31, 2020Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Publication number: 20200407773Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt hereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: September 1, 2020Publication date: December 31, 2020Inventors: Marvin R. GAROVOY, Peter E. HAROLDSEN, Donald G. MUSSON
-
Patent number: 10793893Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: June 29, 2012Date of Patent: October 6, 2020Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Publication number: 20140255380Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: ApplicationFiled: June 29, 2012Publication date: September 11, 2014Applicant: BIOMARIN PHARMACEUTICALS, INC.Inventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 5290781Abstract: This invention relates to the use of ketanserinol as an ophthalmic therapeutic agent to reduce intraocular pressure and its method of use for treating glaucoma by systemic administration of ketanserinol, it salts, esters or prodrugs to a patient or more particularly, topically administering ketanserinol and salts thereof to the eye of a patient.Type: GrantFiled: January 5, 1993Date of Patent: March 1, 1994Assignee: Iolab CorporationInventors: Ramon L. Espino, Donald G. Musson, Orest Olejnik
-
Patent number: 5182270Abstract: Experiments have been performed which test the stability of thymoxamine in aqueous solution at room temperature and above. It was determined that dimethyl-beta-cyclodextrin slows the hydrolysis degradation of thymoxamine while other beta-cyclodextrin analogs either accelerate the hydrolysis degradation or have no effect on the rate of hydrolysis degradation. Cytological experiments have been performed which show that chemical formulations containing thymoxamine and up to 5% by weight dimethyl-beta-cyclodextrin have the same toxicity as chemical formulations with thymoxamine alone.Type: GrantFiled: August 3, 1989Date of Patent: January 26, 1993Assignee: Iolab CorporationInventors: Donald G. Musson, Orest Olejnik